DDW 2022 Pfizer, Eli Lilly, Johnson & Johnson Announce Clinical Trial Results of Inflammatory Bowel Disease

From May 21st to May 24th, the 2022 Digestive Disease Week (DDW) will be held in San Diego, USA in the form of online and offline combination, and comprehensively describe the research status of global gastroenterolo.

01 Pfizer

Pfizer announced results from two pivotal trials including the ELEVATE UC Phase III registration program evaluating the selective sphingosine 1-phosphate (S1P) receptor modulator Etrasimod in the treatment of moderately to severely active ulcerative colit.

In the 52-week ELEVATE UC 52 study, at week 12, the clinical remission rate was 27% in patients taking eztramod, compared with 4% in the placebo group and 31% in the placebo group, That compares with 7% at week 5 In the second trial, ELEVATE UC 12, the clinical response rate was 28% for patients receiving etramod and 12% for patients receiving place.

Notably, Etrasimod was developed by Arena Pharmaceuticals, which Pfizer acquired in March 202

02 Eli Lilly

At the meeting, Eli Lilly announced that its monoclonal antibody mirikizumab, which targets the p19 subunit of IL-23, has achieved positive results in a Phase 3 clinical tri.

Specifically, among patients who received mirikizumab for 12 weeks of induction therapy, 49% of participants reported clinical remission after one year, compared with only 21% in the placebo gro.

In addition, in the first quarter of 2022, Eli Lilly submitted a Biologics License Application to the.

03 Janssen

Johnson & Johnson's Janssen Pharmaceuticals Announces New Data from the Phase 1 GALAXI Trial of TREMFYA ® (guselkumab) in Adult Patients With Moderately to Severely Active Crohn's Disease (CD) and in Ulcers Treated with STLARA ® (ustekinumab) Three independent long-term pooled analyses of adult patients with chronic colitis (UC) and .

GALAXI 1 data show that study participants who had inadequate or intolerant responses to conventional therapy and/or biologics treated with TREMFYA achieved high levels of clinical biomarker responsesa (45-67%), endoscopic responsesb (43-46%) and clinical remission of C-reactive protein (CRP) ≤3 mg/L or fecal calprotectin ≤250 μg/g (33-67%) at 48 weeks across dose grou.

TREMFYA is not approved in the.

In addition, STELARA conducted data from 13 studies across all approved indications, including data for up to one year in psoriatic arthritis [PsA], 2 in UC, and 5 in CD and plaque psoriasis [Ps.

Reference source :

Pfizer and Lilly Zero in on Success in Ulcerative Colitis

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA (guselkumab) and Long-Term Safety Profile for STELARA (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week 2022

After COVID and new global disruptions, Eli Lilly does victory lap with UC data